Summary, Review of Work Group Considerations

Sara Oliver MD, MSPH
Advisory Committee on Immunization Practices
February 27, 2019
Policy Topics Under Consideration

- Consider if the new pediatric hexavalent vaccine should be included as an option in the Vaccines for Children (VFC) Program for the infant series at 2, 4, and 6 months of age

- Consider if the new pediatric hexavalent vaccine should be preferentially recommended for the American Indian/Alaskan Native (AI/AN) population
Information Reviewed by Work Group

- Immunogenicity Data
- Safety Data
- Hib Epidemiology and Hib Vaccines in AI/AN Population
- Pediatric Hexavalent Vaccine and AI/AN Population
Immunogenicity of Pediatric Hexavalent Vaccine

- Non-inferiority criteria met
  - Exceptions:
    - GMC for one Pertussis antigen (FHA) post-dose 3
      - However, achieved with % vaccine response
    - GMC for one Pneumococcal antigen (PN6B) post-dose 3
      - Met non-inferiority endpoints set in PCV13 studies (0.5)
Safety of Pediatric Hexavalent Vaccine

- Safety profile consistent with component vaccines
- Higher rate of fever, particularly compared to pentavalent regimens
  - No increase in fever-related medical events
Current Work Group Thoughts

- Consider if the new pediatric hexavalent vaccine should be included as an option in the VFC Program for the infant series at 2, 4, and 6 months of age
Current Work Group Thoughts

- Consider if the new pediatric hexavalent vaccine should be included as an option in the VFC Program for the infant series at 2, 4, and 6 months of age

  Work Group is supportive of including this vaccine in the VFC program as a recommended option
In the pre-vaccine era, Hib disease occurred at younger age among AI/AN population

PRP-OMP vaccines achieve protective immunity in majority of infants after 1\textsuperscript{st} dose
Hib Epidemiology and Hib Vaccines in AI/AN Population

- In the pre-vaccine era, Hib disease occurred at younger age among AI/AN population

- PRP-OMP vaccines achieve protective immunity in majority of infants after 1st dose

PRP-OMP vaccines have preferential recommendation for AI/AN population
Pediatric Hexavalent Vaccine and AI/AN population

- Vaxelis™ same antigen and manufacturer as PedvaxHIB®
  - PedvaxHIB®: 7.5µg PRP-OMP
  - Vaxelis™: 3µg PRP-OMP

- Previous preferential recommendation based on immunogenicity data after 1st dose
  - Available data for Vaxelis™ shows robust response
    - Post-dose 2, post-dose 3, post-toddler dose
    - No data post-dose 1
Current Work Group Thoughts

- Consider if the new pediatric hexavalent vaccine should be preferentially recommended for the AI/AN population
Current Work Group Thoughts

- Consider if the new pediatric hexavalent vaccine should be preferentially recommended for the AI/AN population

The Work Group feels that immunogenicity data post-dose 1 is needed before ACIP considers a preferential recommendation for the AI/AN population.
Next Steps

- Apply the Evidence to Recommendations Framework
For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.